bevacizumabe
Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By binding VEGF-A, it prevents it from activating VEGF receptors on blood vessels, inhibiting angiogenesis and reducing vascular permeability. This mechanism aims to slow tumor growth and limit cancer-related edema.
Bevacizumab is approved for use in several cancers, most notably in combination with chemotherapy for metastatic
Common and serious adverse effects reflect its anti-angiogenic action. Potential risks include hypertension, arterial thromboembolic events,
Administration is by intravenous infusion, with regimens tailored to the cancer type and patient factors. Bevacizumab